AVP and inappropriate ADH syndrome: Since vaptans directly antagonize the V2R, and SIADH is characterized by inappropriate elevations of AVP or gain-of-function of the V2R, it is not unexpected that vaptans have the highest efficacy in increasing serum sodium compared to the other available therapies for SIADH treatment [38].